Connect with us

Business

AstraZeneca antibody cocktail succeeds in late-stage study to treat COVID-19, company says – Sydney Morning Herald

The findings are a boost to the British drug maker’s efforts to develop coronavirus medicines beyond vaccines.

Published

on

Article feature image

Well be continuing discussions with regulators around this new data, she said of the trial results.
The trial took place across 13 countries and involved more than 900 adult participants, with one half receiving AZD7442 and the rest a placebo. Full trial…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending